NitroMed to axe BiDil reps

Share this article:
NitroMed to axe BiDil reps
NitroMed to axe BiDil reps

NitroMed announced it plans to lay off a majority of its newly hired BiDil sales force by roughly 70 to 90 employees.
 
NitroMed doubled its sales force from 30 to 60 specialist reps during the second half of 2007 to boost BiDil prescriptions. BiDil is indicated for the treatment of heart failure in self-identified black patients.

“However, with only modest improvement in sales, management concluded that it cannot sustain BiDil marketing efforts alone,” wrote Friedman, Billings, Ramsey & Co. analyst Robert Uhl in a recent note to investors.

Nitromed now expects to file the NDA for BiDil XR, the once-daily extended release formulation, with the FDA in 2010.
 
Nitromed has also hired an investment bank to explore strategic options, which could lead to sale of the company, Uhl wrote.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.